Articles from Ventyx Biosciences, Inc.
SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London.
By Ventyx Biosciences, Inc. · Via GlobeNewswire · November 17, 2025
VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide
By Ventyx Biosciences, Inc. · Via GlobeNewswire · October 22, 2025